



Date: 16.01.2025

## **BSE Limited**

Dept. of Corporate Services, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 BSE Scrip Code - 541304

**National Stock Exchange of India Limited** 

Dept. of Corporate Compliances, Exchange Plaza, C-1 Block-G, Bandra Kurla Complex, Bandra (E) Mumbai- 400 051

**NSE Symbol: INDOUS** 

Dear Sir/Madam,

Subject: Compliance under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter Ended 31<sup>st</sup> December, 2024.

Dear Sir,

Pursuant to Regulation 13(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Circular no. SEBI/HO/CFD/CFD-PoD- 2/CIR/P/2024/185 dated 31st December, 2024 issued by the Securities and Exchange Board of India ("SEBI Circular"), read with BSE Circular No. 20250102-4, the Investor Grievance Redressal Report of the Company for the Quarter ended on 31st December, 2024 is given as under in the format prescribed in the above mentioned SEBI Circular.

You are requested to please take on record above said information for your reference.

Thanking you

Yours faithfully,

For, Indo Us Bio Tech Limited

Ms. Dimpy Joshi Company Secretary & Compliance Officer







## Investor Grievance Redressal Report for the Quarter ended December 31, 2024

No. of Investor Complaints pending at the beginning of Quarter	0
No. of Investor Complaints received during the Quarter	0
No. of Investor Complaints disposed off during the Quarter	0
No. of Investor Complaints those remaining unresolved at the end of the Quarter	0

